MarketCap
Facebook
X
TelegramGeschäftsbericht 2023
hinzugefügt 27.03.2024
Ampio Pharmaceuticals Gesamtes Eigenkapital 2011-2026 | AMPE
Gesamtes Eigenkapital Jährlich Ampio Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.36 M | 11.8 M | 27.3 M | 17.5 M | 6.44 M | 5.24 M | -34.2 M | 6.63 M | 37 M | 66.1 M | 33.1 M | 23.8 M | 17.8 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 66.1 M | -34.2 M | 17.1 M |
Gesamtes Eigenkapital Vierteljährlich Ampio Pharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.38 M | 6.56 M | 7.88 M | 11.8 M | 13.8 M | 20.1 M | 22.3 M | 27.3 M | 17.3 M | 20.3 M | 16.8 M | 17.5 M | 17.5 M | 17.5 M | 17.5 M | 6.44 M | 6.44 M | 6.44 M | 6.44 M | 5.24 M | 5.24 M | 5.24 M | 5.24 M | -34.2 M | -34.2 M | -34.2 M | 5 M | 6.63 M | 9.77 M | 13.1 M | 17.9 M | 37 M | 37 M | 37 M | 37 M | 66.1 M | 66.1 M | 66.1 M | 66.1 M | 33.1 M | 33.1 M | 33.1 M | 33.1 M | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 17.8 M | 17.8 M | 17.8 M | 17.8 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 66.1 M | -34.2 M | 18.6 M |
Gesamtes Eigenkapital anderer Aktien in der Pharmaeinzelhändler
| Name | Gesamtes Eigenkapital | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
5.1 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
-16.2 M | - | 2.54 % | $ 160 B | France |
 |
Enlivex Therapeutics Ltd.
ENLV
|
1.93 B | $ 0.8 | -3.61 % | $ 36.6 M |  Israel |
 |
Exelixis
EXEL
|
2.16 B | $ 46.17 | -5.2 % | $ 12.5 B | USA |
 |
Athira Pharma
ATHA
|
27.8 M | - | - | $ 269 M | USA |
 |
Fortress Biotech
FBIO
|
49.9 M | $ 2.42 | -4.9 % | $ 67.5 M | USA |
 |
Heron Therapeutics
HRTX
|
14.3 M | $ 1.23 | -6.11 % | $ 205 M | USA |
 |
Ionis Pharmaceuticals
IONS
|
489 M | $ 75.65 | -1.56 % | $ 12.1 B | USA |
 |
BioNTech SE
BNTX
|
1.37 B | $ 92.69 | -2.7 % | $ 27.2 B | Germany |
 |
Checkmate Pharmaceuticals
CMPI
|
69.5 M | - | - | $ 231 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
830 M | $ 208.55 | -10.32 % | $ 3.81 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
733 M | - | - | $ 3.73 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
315 M | $ 104.1 | -5.43 % | $ 5.23 B | USA |
 |
MannKind Corporation
MNKD
|
-51 M | $ 3.53 | -0.98 % | $ 1.08 B | USA |
 |
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | USA |
 |
Esperion Therapeutics
ESPR
|
-302 M | $ 3.15 | - | $ 655 M | USA |
 |
Matinas BioPharma Holdings
MTNB
|
4.83 M | $ 0.64 | -6.49 % | $ 3.5 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.59 M | - | - | $ 5.93 M | Israel |
 |
Genprex
GNPX
|
7.96 M | $ 0.87 | -2.57 % | $ 811 K | USA |
 |
Nanobiotix S.A.
NBTX
|
70.5 M | $ 43.39 | 3.64 % | $ 286 B | France |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
69.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
-27.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
169 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
78.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
189 M | $ 20.68 | -14.46 % | $ 2.63 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
18.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Genmab A/S
GMAB
|
14 B | $ 27.08 | -2.9 % | $ 16.7 B |  Danmark |
|
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
16.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Applied Therapeutics
APLT
|
-17.1 M | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
10.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-24.2 M | - | 17.91 % | $ 11.1 M | USA |